Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Catherine D. Williams"'
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma
Autor:
Catherine D. Williams, Pamela L. Clemens, Andrew Spencer, Meral Beksac, Yael C Cohen, Ming Qi, Peter M. Voorhees, Christoph Heuck, Ajai Chari, Matthew W Jenner, Philippe Moreau, Michele Cavo, Niels W.C.J. van de Donk, Hartmut Goldschmidt, Irwindeep Sandhu, Steven Kuppens, C. Ola Landgren, Jane Estell, Craig C. Hofmeister, Tobias Neff, Rajesh Bandekar
Publikováno v:
Landgren, C O, Chari, A, Cohen, Y C, Spencer, A, Voorhees, P, Estell, J A, Sandhu, I, Jenner, M W, Williams, C, Cavo, M, van de Donk, N W C J, Beksac, M, Moreau, P, Goldschmidt, H, Kuppens, S, Bandekar, R, Clemens, P L, Neff, T, Heuck, C, Qi, M & Hofmeister, C C 2020, ' Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma : a randomized, open-label, multicenter, phase 2 study (CENTAURUS) ', Leukemia, vol. 34, no. 7, pp. 1840-1852 . https://doi.org/10.1038/s41375-020-0718-z
Leukemia
Leukemia, 34(7), 1840-1852. Nature Publishing Group
Leukemia
Leukemia, 34(7), 1840-1852. Nature Publishing Group
Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURU
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a7432719c5f9d38a656c4ec334643a
https://doi.org/10.1038/s41375-020-0718-z
https://doi.org/10.1038/s41375-020-0718-z
Autor:
Stephen F. Hawkins, James Croft, Faith E. Davies, Holger W. Auner, Catherine D. Williams, Debbie Sherratt, Mamta Garg, Ceri Bygrave, Jamie Cavenagh, Gareth J. Morgan, Ruth M. de Tute, Sarah Brown, Kwee Yong, Louise Flanagan, Neil Rabin, Karthik Ramasamy, Roger G. Owen, Martin Kaiser, Samantha Hinsley
Publikováno v:
Haematologica
The proteasome inhibitors, carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these proteasome inhibitors in combination with cyclophosphamide and d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d159a7e5ec3a60db90a2b9071450df3e
http://hdl.handle.net/10044/1/88418
http://hdl.handle.net/10044/1/88418
Autor:
Peter O'Gorman, Diep Gray, Richard Greil, Julian Cooney, Catherine D. Williams, Zsolt Szabo, Evangelos Terpos, Xavier Leleu, Ramón García Sanz, Jiri Minarik
Publikováno v:
American Journal of Hematology. 91:806-811
Neutropenia is a well-known dose-limiting toxicity associated with lenalidomide plus dexamethasone treatment in patients with multiple myeloma; however, little is known about its management and associated outcomes in the real world setting. The prese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8b750c712b746bdb9261860a983882b
https://doi.org/10.1002/ajh.24416
https://doi.org/10.1002/ajh.24416
Autor:
Lucy Jones, Mike Davies, David S. Gardner, Rebecca Alborough, Catherine D. Williams, C. Davis
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Scientific Reports
Scientific Reports
The mineral content of complete pet food is regulated to ensure health of the companion animal population. A comprehensive analysis of adherence to these regulatory guidelines has not been conducted. We measured mineral composition of a range of comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28262661e5ce21e99d5371d8e3d0ee1d
https://doi.org/10.1038/s41598-017-17159-7
https://doi.org/10.1038/s41598-017-17159-7
Autor:
Catherine D. Williams
Publikováno v:
Critical Social Policy. 38:619-620
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc54a55e679bc2effa21d0ae881aea75
https://doi.org/10.1177/0261018318766988e
https://doi.org/10.1177/0261018318766988e
Autor:
Varnia Hungria, Roman Hájek, David S. Siegel, Thorsten Graef, Joseph E. Eid, Scott Vuocolo, Hilary A. Blacklock, Catherine D. Williams, Laura Rosiñol, Andrew Spencer, Kenneth C. Anderson, Junyuan Qi, Sagar Lonial, Thierry Facon, Hartmut Goldschmidt, Jennifer Houp, Meletios A. Dimopoulos, L. Sun, Antonio Palumbo
Publikováno v:
The Lancet Oncology. 14:1129-1140
Summary Background We aimed to assess efficacy and tolerability of vorinostat in combination with bortezomib for treatment of patients with relapsed or refractory multiple myeloma. Methods In our randomised, double-blind, placebo-controlled, phase 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::663cd55955b1420c133627f8a1c50565
https://doi.org/10.1016/s1470-2045(13)70398-x
https://doi.org/10.1016/s1470-2045(13)70398-x
Autor:
Jessica Kendall, Ceri Bygrave, Sarah Brown, Mamta Garg, Ruth M. de Tute, Neil Rabin, Kwee Yong, Catherine D. Williams, Debbie Sherratt, Faith E. Davies, Samantha Hinsley, Karthik Ramasamy, Holger W. Auner, Jamie Cavenagh, Martin Kaiser, Stephen F. Hawkins, Roger G. Owen, Louise Flanagan, Gareth J. Morgan
Publikováno v:
Blood. 132:306-306
Background Carfilzomib (K) and bortezomib (V) and have been studied in head-to-head comparison using a K dose of 56mg/m2 in doublet with dexamethasone at relapse (ENDEAVOR), and also at 36mg/m2 in triplet with melphalan and prednisolone in newly diag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25f8c61536d1d448491b83b64625280a
https://doi.org/10.1182/blood-2018-99-116624
https://doi.org/10.1182/blood-2018-99-116624
Autor:
Andrew Spencer, Homer Adams, Ming Qi, Michele Cavo, Jane Estell, Meral Beksac, Steven Kuppens, Hartmut Goldschmidt, Rajesh Bandekar, Yael C Cohen, Craig C. Hofmeister, Catherine D. Williams, Ola Landgren, Peter M. Voorhees, Matthew W Jenner, Niels W.C.J. van de Donk, Tobias Neff, Ajai Chari, Irwindeep Sandhu, Annelore Cortoos, Pamela L. Clemens, Philippe Moreau
Publikováno v:
Blood. 132:1994-1994
Introduction: Multiple myeloma (MM) evolves from precursor disorders such as monoclonal gammopathy of undetermined significance (MGUS) and SMM (Landgren O, et al. Blood 2009. 113[22]:5412-5417). Currently, there are no approved therapies for SMM, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c287f99bb04bea0db657c6a3aa303b11
https://doi.org/10.1182/blood-2018-99-113467
https://doi.org/10.1182/blood-2018-99-113467
Autor:
Louise Flanagan, Debbie Sherratt, Karthik Ramasamy, Sarah Brown, Gareth J. Morgan, Ruth M. de Tute, Jamie Cavenagh, Neil Rabin, Martin Kaiser, Roger G. Owen, Mamta Garg, Kwee Yong, Faith E. Davies, Catherine D. Williams, Holger W. Auner, Samantha Hinsley
Publikováno v:
Blood. 132:802-802
Background The benefit of single agent maintenance is largely established from studies in newly diagnosed patients, while extended therapy combination regimens are more commonly used in relapsed disease. Extended therapy on combination protocols may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56fa9b011e11f497f7b3acb287f0c77e
https://doi.org/10.1182/blood-2018-99-116426
https://doi.org/10.1182/blood-2018-99-116426
Autor:
Roger G. Owen, Walter M Gregory, Anna Hockaday, Alina Striha, Corinne Collett, Matthew W Jenner, Jindriska Lindsay, Nigel H. Russell, Kamaraj Karunanithi, Gordon Cook, Gareth J. Morgan, Charlotte Pawlyn, Mamta Garg, Catherine D. Williams, Mark T. Drayson, Martin Kaiser, David A Cairns, Faith E. Davies, John R Jones, Graham Jackson, Bhuvan Kishore
Publikováno v:
Blood. 132:302-302
Background Darwinian evolution drives multiple myeloma (MM) and leads to diversity both within and between patients. This suggests the need for combinations of agents with different mechanisms of action targeting sub-clonal populations to maximize th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::104a8b4c12af2ca09d90b97b93a5735b
https://doi.org/10.1182/blood-2018-99-114956
https://doi.org/10.1182/blood-2018-99-114956